The Groundbreaking SAMRC Findings on CKD in Africa

A recent announcement from the South African Medical Research Council (SAMRC) has brought urgent attention to chronic kidney disease (CKD), revealing that it impacts approximately 1 in 7 adults across Africa. This figure surpasses global averages and underscores a silent epidemic straining healthcare systems continent-wide. Drawing from the Global Burden of Disease (GBD) Study 2023 data published in The Lancet, SAMRC researchers highlighted how CKD ranks as the ninth leading cause of death globally, with Africa's burden even more pronounced due to unique regional challenges.

Spearheaded by experts like Dr. Cindy George and Dr. Dipuo Motshwari from SAMRC's Non-Communicable Diseases Research Unit (NCDRU), this insight emphasizes the critical role of South African universities in advancing medical research. Institutions such as the University of Cape Town (UCT), Stellenbosch University, and Cape Peninsula University of Technology (CPUT) collaborate closely with SAMRC, fostering interdisciplinary teams that drive discoveries with real-world impact.

What is Chronic Kidney Disease?

Chronic kidney disease refers to the gradual loss of kidney function over time, often progressing through five stages based on glomerular filtration rate (GFR), a measure of how well kidneys filter waste from blood. In stage 1, kidneys are damaged but function normally (GFR ≥90 mL/min); by stage 5, end-stage renal disease (ESRD), GFR falls below 15 mL/min, requiring dialysis or transplant.

Commonly asymptomatic in early stages, CKD is dubbed the 'silent killer' because symptoms like fatigue, swelling, and high blood pressure emerge late. Globally, most cases are stages 1-3, where interventions can slow progression. In Africa, rapid advancement to advanced stages heightens urgency for higher education-driven research into early biomarkers and affordable diagnostics.

Unpacking the Study Methodology

The revelations stem from the GBD 2023 analysis, a comprehensive systematic review pooling data from thousands of studies worldwide spanning 1990-2023. It estimates CKD prevalence using age-standardised rates for adults aged 20+, accounting for GFR and albuminuria levels via modelling techniques like Bayesian meta-regression and DisMod-MR.

SAMRC's involvement through the CKD-Africa collaboration pooled individual participant data from 39 African studies across 12 countries, totaling over 35,000 participants, mostly from sub-Saharan Africa. This pan-African effort, hosted by SAMRC, integrates university-led cohorts from UCT's Kidney and Hypertension Research Unit and Stellenbosch's nephrology teams, enhancing data quality for region-specific insights.

Prevalence Disparities: Africa Leads the Global Burden

Globally, CKD affects 788 million adults (14.2% age-standardised prevalence in 2023), nearly doubling from 378 million in 1990. Yet Africa's rates exceed this: sub-Saharan Africa at 15.6% (69.5 million cases), with Southern sub-Saharan Africa at 18.3%. This translates to roughly 1 in 7 adults continent-wide, far above high-income regions' 10.8%.

In South Africa, university-linked studies report prevalence up to 20% in high-risk groups like those with diabetes or hypertension. The GBD data, amplified by SAMRC, signals CKD as Africa's growing threat, outpacing communicable diseases in some areas.

Regional Hotspots and Vulnerable Populations

Western sub-Saharan Africa sees 17.2% prevalence (30.3 million cases), driven by genetics like APOL1 variants in Nigeria. Central SSA hits 17.7%, Eastern 12.5%. High-burden nations include Nigeria (20.3%, 16.1 million cases) and South Africa.

Women face higher rates due to gestational risks; rural poor suffer from limited access. SA universities like UKZN contribute data showing HIV-accelerated CKD, where prevalence reaches 20-30% in people living with HIV.

Photo by Hennie Stander on Unsplash

Driving Risk Factors in the African Context

Top attributable risks mirror global: high fasting glucose (31.9%), systolic blood pressure (24.5%), BMI (23.5%). In Africa, add HIV (accelerates progression), poverty-linked infections, toxins, and climate extremes. Hypertension prevalence exceeds 30% in SA urban blacks; diabetes surges with urbanisation.

CPUT/SAMRC's Cardiometabolic unit researches metabolic links, revealing how low fruit/veg intake and sodium-heavy diets exacerbate issues. Universities train clinicians for culturally attuned screening.

South African Universities Powering CKD Research

SA higher education anchors SAMRC efforts. UCT's Ikechi Okpechi leads global CKD metrics; Stellenbosch's Prof. Razeen Davids advances epidemiology. CPUT hosts NCDRU, alma mater to Dr. Motshwari. Wits and UKZN contribute genomic data via KidneyGenAfrica.

These institutions secure SAMRC grants, train PhDs in nephrology, and foster pan-African networks. Careers in kidney research boom, with roles in epidemiology, genetics, and policy at unis like UCT's Division of Nephrology.

SAMRC's Leadership and University Partnerships

SAMRC, via CKD-Africa (chaired by Dr. George), harmonises data for robust estimates. Partnerships with 12 countries amplify SA unis' reach. Funded extramural projects at Stellenbosch develop GFR equations for Africans, outperforming Western formulas.

This model exemplifies higher ed's translational role, turning data into policy via WHO collaborations. Students gain hands-on experience, preparing for global health challenges.

Healthcare and Economic Implications

CKD causes 1.48 million global deaths yearly; Africa's DALYs exceed global averages by 70%+. ESRD overwhelms dialysis capacity—SA has 7000 slots for 40,000 needy. Economic toll: billions in lost productivity.

Unis advocate integrated care; UCT models show early screening saves R10bn annually in SA.

Challenges: Underdiagnosis and Access Gaps

Early CKD detection lags—only 35% diabetics screened globally, worse in Africa. Costly albuminuria tests absent in rural clinics. Genetic factors like APOL1 demand tailored approaches.

SA unis pioneer low-cost biomarkers; SAMRC funds portable diagnostics at CPUT.

Photo by Karabo Mdluli on Unsplash

Prevention: Actionable Strategies from Research

• Blood Pressure Control: Target <130/80 mmHg with ACE inhibitors.
• Glycemic Management: SGLT2 inhibitors slow progression 30-40%.
• Lifestyle: Reduce salt, boost activity; unis promote community programs.
• Screening: Annual GFR/albuminuria for at-risk groups.

Stellenbosch trials community education via nursing students.

Future Outlook: Expanding University-Led Initiatives

SAMRC calls for scaled genomics (KidneyGenAfrica at Wits) and trials. SA unis eye AI for prediction models. With NSF/NRF funding, PhD opportunities surge in nephrology.

Prospects brighten for researchers tackling Africa's CKD crisis through collaborative higher ed efforts.

For deeper insights, read the full GBD CKD study in The Lancet.